Pharmacological NAD-boosting strategies improve mitochondrial homeostasis in human complex i-mutant fibroblastss

Molecular Pharmacology

Volumn 87, Issue 6, 2015, Pages 965-971

  Felici, Roberta ^a   Lapucci, Andrea ^a   Cavone, Leonardo ^a   Pratesi, Sara ^b   Berlinguer Palmini, Rolando ^c   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; IRON SULFUR PROTEIN; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE) IRON SULFUR PROTEIN 1; UNCLASSIFIED DRUG; NDUFS1 PROTEIN, HUMAN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE-BETA-RIBOSIDE; PARP1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE;

ARTICLE; CELL MUTANT; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FIBROBLAST; HOMEOSTASIS; HUMAN; HUMAN CELL; INFANT; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; LEUKOENCEPHALOPATHY; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION;

ENERGY METABOLISM; FIBROBLASTS; HOMEOSTASIS; HUMANS; INFANT; LEUKOENCEPHALOPATHIES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MUTATION; NAD; NADH DEHYDROGENASE; NIACINAMIDE; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 84936144126     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097204     Document Type: Article

References (40)

1. Bai P, Canto C, Brunyánszki A, Huber A, Szántó M, Cen Y, Yamamoto H, Houten SM, Kiss B, and Oudart H et al. (2011a) PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 13:450-460.
2. Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, and Houtkooper RH et al. (2011b) PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 13:461-468.
3. Berridge MV and Tan AS (1993) Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303:474-482.
4. Bieganowski P and Brenner C (2004) Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117:495-502.
5. Bugiani M, Invernizzi F, Alberio S, Briem E, Lamantea E, Carrara F, Moroni I, Farina L, Spada M, and Donati MA et al. (2004) Clinical and molecular findings in children with complex I deficiency. Biochim Biophys Acta 1659:136-147.
6. Canto C and Auwerx J (2011) NAD1 as a signaling molecule modulating metabolism. Cold Spring Harb Symp Quant Biol 76:291-298.
7. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, and Cettour-Rose P et al. (2012) The NAD (+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15:838-847.
8. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, and Zeviani M (2014) NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042-1049.
9. Chi Y and Sauve AA (2013) Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care 16:657-661.
10. Chiarugi A, Dölle C, Felici R, and Ziegler M (2012) The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer 12:741-752.
11. DiMauro S and Mancuso M (2007) Mitochondrial diseases: therapeutic approaches. Biosci Rep 27:125-137.
12. Dimauro S and Rustin P (2009) A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 1792:1159-1167.
13. DiMauro S and Schon EA (2008) Mitochondrial disorders in the nervous system. Annu Rev Neurosci 31:91-123.
14. Dölle C, Skoge RH, Vanlinden MR, and Ziegler M (2013) NAD biosynthesis in humans - enzymes, metabolites and therapeutic aspects. Curr Top Med Chem 13:2907-2917.
15. Fato R, Bergamini C, Leoni S, Strocchi P, and Lenaz G (2008) Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res 33:2487-2501.
16. Felici R, Cavone L, Lapucci A, Guasti D, Bani D, and Chiarugi A (2014) PARP inhibition delays progression of mitochondrial encephalopathy in mice. Neurotherapeutics 11:651-664.
17. Felici R, Lapucci A, Ramazzotti M, and Chiarugi A (2013) Insight into molecular and functional properties of NMNAT3 reveals new hints of NAD homeostasis within human mitochondria. PLoS ONE 8:e76938.
18. Frizzell KM, Gamble MJ, Berrocal JG, Zhang T, Krishnakumar R, Cen Y, Sauve AA, and Kraus WL (2009) Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J Biol Chem 284:33926-33938.
19. Hossain MB, Ji P, Anish R, Jacobson RH, and Takada S (2009) Poly(ADP-ribose) polymerase 1 interacts with nuclear respiratory factor 1 (NRF-1) and plays a role in NRF-1 transcriptional regulation. J Biol Chem 284:8621-8632.
20. Houtkooper RH and Auwerx J (2012) Exploring the therapeutic space around NAD+. J Cell Biol 199:205-209.
21. Iuso A, Scacco S, Piccoli C, Bellomo F, Petruzzella V, Trentadue R, Minuto M, Ripoli M, Capitanio N, and Zeviani M et al. (2006) Dysfunctions of cellular oxidative metabolism in patients with mutations in the NDUFS1 and NDUFS4 genes of complex I. J Biol Chem 281:10374-10380.
22. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Jr, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, and Tian R (2013) Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab 18:239-250.
23. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsström S, Pasila L, Velagapudi V, Carroll CJ, and Auwerx J et al. (2014) Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 6:721-731.
24. Koch-Nolte F, Haag F, Guse AH, Lund F, and Ziegler M (2009) Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 2:mr1.
25. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, and Kraus WL (2008) Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 319:819-821.
26. Krishnakumar R and Kraus WL (2010) PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell 39:736-749.
27. Lapucci A, Pittelli M, Rapizzi E, Felici R, Moroni F, and Chiarugi A (2011) Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol 79:932-940.
28. Luo X and Kraus WL (2012) On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26:417-432.
29. Moslemi AR and Darin N (2007) Molecular genetic and clinical aspects of mitochondrial disorders in childhood. Mitochondrion 7:241-252.
30. Murphy MP and Smith RA (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47:629-656.
31. Pirinen E, Cantó C, Jo YS, Morato L, Zhang H, Menzies KJ, Williams EG, Mouchiroud L, Moullan N, and Hagberg C et al. (2014) Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 19:1034-1041.
32. Pittelli M, Felici R, Pitozzi V, Giovannelli L, Bigagli E, Cialdai F, Romano G, Moroni F, and Chiarugi A (2011) Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol Pharmacol 80:1136-1146.
33. Sauve AA (2008) NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 324:883-893.
34. Scarpulla RC, Vega RB, and Kelly DP (2012) Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 23:459-466.
35. Skladal D, Halliday J, and Thorburn DR (2003) Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 126:1905-1912.
36. Soldatenkov VA, Chasovskikh S, Potaman VN, Trofimova I, Smulson ME, and Dritschilo A (2002) Transcriptional repression by binding of poly(ADP-ribose) polymerase to promoter sequences. J Biol Chem 277:665-670.
37. Spinazzola A and Zeviani M (2009) Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J Intern Med 265:174-192.
38. von Kleist-Retzow JC, Cormier-Daire V, de Lonlay P, Parfait B, Chretien D, Rustin P, Feingold J, Rötig A, and Munnich A (1998) A high rate (20%-30%) of parental consanguinity in cytochrome-oxidase deficiency. Am J Hum Genet 63:428-435.
39. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283:1482-1488.
40. Yap TA, Sandhu SK, Carden CP, and de Bono JS (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61:31-49.